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Available online 19 April 2016Parkinson's disease is a commonneurodegenerative disorder, which is due to the loss of dopaminergic neurons in
the substantia nigra pars compacta (SNpc) and for which no deﬁnitive cure is currently available. Cellular
functions in mouse and human tissues can be restored after fusion of bone marrow (BM)-derived cells with a
variety of somatic cells. Here, after transplantation of hematopoietic stem and progenitor cells (HSPCs) in the
SNpc of two different mouse models of Parkinson's disease, we signiﬁcantly ameliorated the dopaminergic
neuron loss and function.We show fusion of transplanted HSPCs with neurons and with glial cells in the ventral
midbrain of Parkinson's diseasemice. Interestingly, the hybrids can undergo reprogramming in vivo and survived
up to 4weeks after transplantation,while acquiring features ofmature astroglia. These newly generated astroglia
producedWnt1 andwere essential for functional rescue of the dopaminergic neurons. Our data suggest that glial-
derived hybrids produced upon fusion of transplanted HSPCs in the SNpc can rescue the Parkinson's disease
phenotype via a niche-mediated effect, and can be exploited as an efﬁcient cell-therapy approach.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Intracerebral transplantation1. Introduction
Cellular plasticity in mouse and human tissues can be modulated
after fusion of bone marrow (BM)-derived cells with a variety of cells,
such as neurons, hepatocytes, cardiomyocytes, and gut cells (Nygren
et al., 2004; Doyonnas et al., 2004; Ogle et al., 2005; Johansson et al.,
2008; de Jong et al., 2012). The hybrids produced can repair the function
of these different cell types in a damaged organ (Wang et al., 2003;
Johansson et al., 2008; Sanges et al., 2013).
Parkinson's disease (PD) is one of themost common neurodegener-
ative disorders, and it affects about 1% of the population above the age of
60 years (de Rijk et al., 1997). PD develops due to the loss of dopaminer-
gic neurons in the substantia nigra pars compacta (SNpc), with the con-
sequent degeneration of tyrosine-hydroxylase ﬁbers in the striatum
(CPu, caudate-putamen), and dopamine (DA) depletion (de Rijk et al.,
1997). No deﬁnitive cure is currently available for PD.ulation (CRG), The Barcelona
elona 08003, Spain.
. This is an open access article underWeaimed here to determinewhether transplantation of hematopoi-
etic stem and progenitor cells (HSPCs) in two different PD mouse
models can rescue the loss of dopaminergic neurons after fusion.
HSPCs are currently used in clinical-trial protocols (Chen et al., 2014a,
2014b; Park et al., 2015), which suggests their safety.
The neurotoxin 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine
(MPTP) can induce parkinsonian syndrome in humans that is almost in-
distinguishable fromPD. This treatment produces a dramatic bilateral de-
generation of tyrosine-hydroxylase-positive (TH+) neurons in the SN,
and of TH+ ﬁbers in the striatum (Bové and Perier, 2012). The neurotox-
in 6-hydroxydopamine (6OHDA) triggers death of dopaminergic neu-
rons when injected directly into the brain. Unilateral 6OHDA-injection
has also been described as a ‘hemiparkinson model’, whereby the intact
hemisphere serves as the internal control for the resulting asymmetric
and quantiﬁable motor behavior impairment (Bové and Perier, 2012).
Cell therapy of PD is currently pursed in the striatum, through the in-
crease of DA levels (Meyer et al., 2010). Here, however, we transplanted
HSPCs into the SNpc of bothMPTP and 6OHDAmouse models, with the
aim being to regenerate or protect the loss of dopaminergic neurons.
We show that transplanted HSPCs can fuse with neurons and glial
cells in both PD models. The glial-derived hybrids survive over thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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astroglia and secrete Wnt1. A niche-effect was associated with an im-
portant attenuation of dopaminergic neuronal degeneration. As
a consequence, functional amelioration of the PD phenotype was
observed. The activity of the Wnt signaling pathway was required for
this phenotype rescue.
2. Materials and Methods
2.1. Mice
The mice were housed in accordance with the Ethical Committee
for Animal Experimentation of the Government of Catalonia, and the
experiments were performed in accordance with the rules set by the
local Animal Ethics Committee. ARRIVE (Animal Research: Reporting
of In Vivo Experiments) guidelines (Kilkenny et al., 2010) were
followed.
All of the mice in this study were generated in a wild-type C57BL/6J
background. Here, we usedwild-type C57BL/6J and the following trans-
genic mice: CAG-Cre (Hayashi and McMahon, 2002), β-actin-Cre
(Srinivas et al., 2001), CAG-RFP (Long et al., 2005), GFAP-Cre
(Gregorian et al., 2009), FoxA2-Cre (Park et al., 2008), R26Y (Srinivas
et al., 2001), and ROSA26iDTR (Buch et al., 2005a, 2005b).
2.2. Establishment of the MPTP/6OHDA Mouse Models
For the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)
mousemodel, 8- to 12-week-oldmalemice received one intraperitone-
al injection of MPTP-HCl per day (30 mg/kg free base; Sigma) for ﬁve
consecutive days, according to the sub-acute MPTP injection paradigm
(Vila et al., 2001). Control mice received 0.9% sterile saline injections
only. For the 6-hydroxydopamine (6OHDA) mouse model, either male
or female mice had 6OHDA injected into the right substantia nigra
(SNpc) pars compacta (Parish et al., 2001), under anesthesia and
analgesia (2% isoﬂurane in 2:1 oxygen/nitrous oxide), using a Kopf ste-
reotaxic frame (Kopf Instruments) and a 5 μl Hamilton syringe ﬁtted
with a ﬁne capillary. The 6OHDA was used at 1.5 μg/μl (calculated as
the free base; Sigma) dissolved in a solution of 0.2 mg/ml ascorbic
acid in 0.9% sterile saline. A single injection of 2 μl was performed
using the stereotaxic coordinates according to Paxinos and Franklin
(2008):−3.0 mm anterior/posterior, 1.05 mm lateral with respect to
the bregma, and−4.7 mm ventral from the dura, with a ﬂat skull posi-
tion. Injections were made at a rate of 0.25 μl/min with a further 4 min
allowed for the toxin to diffuse before slowwithdrawal of the capillary,
followed by cleaning and suturing of the wound. For all in vivo experi-
ments, animals were randomized into cages by the animal facility
staff, so that the investigator did not select groups based on size or
appearance. Establishment of Parkinson's disease model (MPTP and
6OHDA) and the subsequent treatments received were randomly
applied on the animals in each cage. Additionally, experiments with
mortality rate over 50% after MPTP intoxication were discarded.
The sole exclusion criterion was death of the subject animal (due to
complications linked with the surgical procedure).
2.3. Cell Preparation and Transplantation
Just before the transplantation, lineage-negative HSPCs were isolat-
ed from the total bone marrow of donor mice using Lineage Cell Deple-
tion kits (Miltenyi Biotech). At day 3 after the last MPTP injection or the
6OHDA infusion, the recipient mice were placed into a Kopf stereotaxic
frame and received one injection of approximately 60,000 cells
suspended in 2 μl phosphate-buffered saline (PBS) over the right
substantia nigra (stereotaxic coordinates were determined according
to Paxinos and Franklin (2008): −2.9 mm anterior, 1.3 mm lateral
with respect to the bregma, and−4.5 mm ventral from the dura, with
a ﬂat skull position. The intracerebral injection was performed using a5 μl Hamilton microsyringe coupled with a 33-gauge needle. Cell infu-
sionswere performed at a rate of 0.5 μl/min. On completion of the injec-
tion, the needle was left in place for 4min before being retracted slowly
at a rate of 1mm/min, to avoid reﬂux along the injection track. After the
surgery, the mice were placed under a warm lamp until their complete
awakening. To block the Wnt/β-catenin signaling by infusion of
Dckkopf-1 (Dkk1) into the SNpc in vivo, the recombinant Dkk1 protein
(R&D Systems, MN, USA) was dissolved in sterile physiological saline
(0.9% NaCl) at a ﬁnal concentration of 1 μg/μl. One infusion of Dkk1
was carried out unilaterally into the SNpc using a 5 μl Hamilton
microsyringe and 2 μg/infusion at the same time of the cell
transplantation.
2.4. Tamoxifen Treatment for Cre-recombinase Induction and Diphtheria
Toxin Injection
To induce Cre recombination for the YFP labeling, 20 mg tamoxifen
(T5648, Sigma) was dissolved in 100 μl ethanol and 900 μl corn oil at
56 °C for 2–3 hours. Tamoxifen was stored in the dark at 4 °C until
use, for up to 3 weeks. Tamoxifenwaswarmed to 37 °C before adminis-
tration. Themice received intraperitoneal injections of a total 75mg ta-
moxifen/kg body weight, once per day for three consecutive days. To
ablate the hybrid cells, ROSA26iDTR transgenic mice were injected in-
traperitoneally with 525 ng diphtheria toxin (D0564, Sigma-Aldrich,
St. Louis, MO, USA) in 300 ml PBS per injection, for four consecutive
days.
2.5. Neurochemical Analysis
Tissue DA, DOAPC andHVA contentwere determined on tissue sam-
ples from striatum (CPu, caudate‐putamen) and cortex (Ctx) by HPLC
with electrochemical detection (Waters model 2465; +0.7 V) as previ-
ously described (Bortolozzi and Artigas, 2003). Mice were killed and
their brainswere quickly removed and placed over a cold plate. Caudate
putamen (CPu) and cortex were carefully dissected out, weight, frozen
on dry ice and kept at−80 °C until assayed. The tissue were homoge-
nized in 200 μl of buffer containing 0.4 M perchloric acid containing
0.1% sodiummetabisulphite, 0.01% EDTA, 0.1% cysteine and centrifuged
at 12,000 g for 30 min. Aliquots of supernatants were then ﬁltered
through 0.45 μm ﬁlters (Millex, Barcelona, Spain) and analyzed by
HPLC as described. The mobile phase consisted of 0.1 M KH2PO4,
1 mM octyl sodium sulphate, 0.1 mM EDTA (pH 2.65) and 18% metha-
nol. DA and their metabolites were separated on a Mediterranea Sea
(C18, 3 μm, 10 cm × 6.4 mm) (Teknokroma, ref TR010042, Barcelona,
Spain).
2.6. Animal Behavior Studies
The motor responses to sensory stimuli in the MPTP-treated mice
were measured using the adhesive removal test. Two training trials
were performed prior to the surgery, with an adhesive dot sticker
(0.6 cm diameter, Avery) placed on the plantar surface of the forelimb.
At 4 weeks after Sham or HSPC transplantation of the MPTP-treated
mice, the adhesive dot sticker was placed on the forelimb, and the
time to make contact and to remove the sticker from the forelimb was
recorded. If a mouse did not remove the sticker within 60 seconds (s),
it received a score of 60 s. The mean data were calculated across three
trials, at one per day. Immediately after this test, the spontaneous
activity test was run in the cylinder, by placing the mice into a small
transparent cylinder (height, 15.5 cm; diameter, 12.7 cm). The sponta-
neous activity was videotaped for 3 minutes, and the number of rears
and the time spent grooming were measured. To test forepaw akinesia
in the 6OHDA mouse model, lesioned mice were randomly assigned to
each treatment group, as the Saline group, the control group
(6OHDA + Sham), and the group for the transplantation of the HSPCs.
To test the spontaneous use of the forelimbs, the cylinder test was
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The mice were videotaped in the glass cylinder for 3 min, in the light.
The cylinder was placed on a piece of glass and a mirror was positioned
at an angle beneath the cylinder to allow a clear view of the motor
movements along the ground as well as along the walls of the cylinder.
The number of contacts during rearing (measured as the number of
supporting touches performed against the cylinder wall) was counted
for each paw. The datawere presented as the percentage of contralater-
al paw use over the total contacts. The accelerating rotarod test was
used to evaluate the locomotor ability of the mice following MPTP, as
described previously (Keshet et al., 2007).
2.7. Unbiased Stereological Cell Counting and Optical
Density Measurements
Blinded observers performed all of the assessments. Immunohisto-
chemical staining of the midbrain was examined (n = 12 sections/
animal) using an optical microscope (Leica, France) equipped with the
CAST semiautomatic stereological software (VisioPharm). Then, the
total numbers of neurons stained for tyrosine‐hydroxylase (TH) and
Nissl in the substantia nigra (SN) were counted stereologically. TH+
neuron ﬁbers in the striatumwere analyzed according to optical density
measurements (n = 6 sections/animal). The Image J processing soft-
ware (National Institutes of Health) was used to analyze the images.
These were thresholded to limit measurements to the TH+ ﬁbers, and
then an integrated density measurement was obtained by multiplying
the TH-stained area by the mean pixel intensity. The TH neuron counts
and the optical density of their ﬁbers are expressed asmeans± s.e.m. of
the percentages of the TH+ cell counts and ﬁbers of the saline controls.
2.8. Quantiﬁcation and Statistical Analysis
A confocal laser-scanning microscope (Leica TCS-SP5) was used
to quantify the immunopositive cells in the sections. All of the quantiﬁ-
cation of the immunostaining was based on analysis of at least ﬁve
sections per mouse, from at least three mice. Serial coronal brain sec-
tions in the region between−2.06 mm and−3.88 mm from the breg-
ma (Paxinos and Franklin, 2008) (Fig. S1a) were selected and used to
quantify the stained areas. The incidence of YFP-immunopositive cells
was expressed either relative to the DAPI-stained nuclei (series of
sections of themidbrain) or to the number of RFP+cells for the reporter
mice. The data are expressed as means ± s.e.m. of the number of tests
stated. Statistical comparisons were made using either Student's t-
tests for two independent samples or analysis of variance by one-way
ANOVA followed by Bonferroni's multiple comparison post-hoc tests,
as indicated in the Figure legends. All of the statistical tests and graphi-
cal presentations were performed using the Prism 5.0 software
(GraphPad, SanDiego, CA). P b 0.05was taken as statistically signiﬁcant.
The distribution and variance were normal and similar in all groups
statistically compared.
2.9. Other Experimental Procedures
Other experimental procedures are described in the Supplementary
experimental procedures. These include immunoﬂuorescence and
histological analysis, FACS analysis, quantitative real time RT-PCR,
microarray analysis, and Western blotting.
3. Results
3.1. Transplantation of HSPCs Above the SNpc Ameliorates Dopaminergic
Neuron Loss and Function
We have previously shown that transplantation of HSPCs can rescue
mouse retinal degeneration (Sanges et al., 2013). The aim here was to
determine whether HSPCs can rescue the PD phenotype after theirtransplantation into the midbrain of the MPTP and 6OHDA mouse
models. Thus HSPCs puriﬁed from donor mice were unilaterally
transplanted above the right SNpc (Fig. 1a).
MPTP and 6OHDA treatments can produce a broad range of mild to
severe motor alterations in mice (Meredith and Kang, 2006). In the
MPTPmodel, we examined sensorimotor deﬁcits using the adhesive re-
moval test and the cylinder test (Fleming et al., 2013). In MPTP-treated
mice transplanted with HSPCs, the removal time was signiﬁcantly less
in comparison to sham mice (Fig. 1b). In addition, in the cylinder test,
there was signiﬁcantly higher spontaneous activity in the group of
HSPC-transplanted mice, with respect to the saline group (Fig. 1b).
The rotaroad test is generally used when large doses of MPTP are ad-
ministered (Duty and Jenner, 2011), a condition different from the
sub-acute regimen of MPTP used in the present study. Nevertheless,
we observed motor function recovery in the rotarod test in the group
of HSPC-transplanted mice 14 days after transplantation. However,
no signiﬁcant differences were seen between the Sham and HSPC-
transplantedmice at 28 days after transplantation, due to the behavioral
recovery of the Sham group (Fig. S1a).
Using an unbiased stereology system, we then quantiﬁed the
number of TH‐immunoreactive cells in the SNpc and the density of
TH+ ﬁbers in the striatum, by optical densitometry. Representative
immunohistochemical images showed attenuation of DA neuron de-
generation after HSPC transplantation (Fig. 1c; compare Saline, Sham,
HSPC groups). Four weeks after transplantation, the percentage of
TH+ cells in the sham-transplanted MPTP-lesioned mice remained
very low bilaterally, with up to a 42.55 ± 5.36% loss of DA neurons
and up to 46.19 ± 4.96% loss of ﬁbers, in comparison with saline-
treated animals (Fig. 1d). Interestingly, in the group of HSPC-
transplanted MPTP-lesioned mice, the loss of TH+ cells in the SNpc
was only around 20.19 ± 4.24%, and the density of TH+ ﬁbers in the
striatum was around 26.72 ± 1.86%, compared to saline-treated
animals. Thus, there was signiﬁcant reduction in MPTP-induced loss of
dopaminergic neurons in HSPC-transplanted mice (Fig. 1d). As a
control, we transplanted lineage+ (Lin+) cells puriﬁed from the BM
of donor mice, and we observed that the reduction in dopaminergic
neurons was comparable in the Lin+ and Sham-transplanted mice
(Fig. S1b, c).
We then carried out biochemical measures of the levels of DA and its
metabolites in the striatum (Caudate-putamen; CPu) and cortex (Ctx)
of HSPC-transplanted mice and controls. There was depletion of
CPu and Ctx DA and of the 3.4-dihydroxyphenylacetic acid (DOPAC)
and homovanillic acid (HVA) DA metabolites after MPTP administra-
tion, with the HSPC-transplanted mice showing a trend toward amelio-
ration in terms of DA in both the CPu and Ctx, and DOPAC and HVA in
the Ctx (Fig. S1d). Interestingly, 4 weeks after transplantation, in the
MPTP + HSPC transplanted mice the metabolite to DA ratio (HVA/
DA), a parameter associated to DA turnover in dopaminergic terminals
(Decressac et al., 2012), was signiﬁcantly lower with respect to the
MPTP + Sham mice, in both the CPu and Ctx (Fig. 1e). Furthermore,
the DOPAC/DA ratio was also signiﬁcantly diminished in the CPu of
HSPC-transplanted mice (Fig. 1e). These data suggest that DA synthesis
and storage was increased after HSPC transplantation in both the stria-
tum and Ctx.
Studies have reported that 6OHDA-lesioned mice show behavioral
impairments more clearly (Schallert et al., 2000; Meredith and Kang,
2006); in addition, the intact side serves as the internal control for the
lesioned side and its responsiveness to HSPC transplantation. Therefore,
we monitored forepaw akinesia of 6OHDA-lesioned mice from 4 to
8 weeks after HSPC transplantation, using the cylinder test. In line
with previous studies, 6OHDA lesion reduced the use of the contralater-
al paw (Schallert et al., 2000). Intracerebral HSPC transplantation
restored this deﬁciency in the grafted mice, an effect that remained
signiﬁcant up to at least 4 weeks (Fig. 1f).
The 6OHDA injections resulted in a loss of DA cells down to 41.08±
9.00% of control levels and a loss of ﬁbers down to 46.66 ± 12.58%
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the contralateral, left hemisphere side (Fig. 1g, LH), which was not
injected with 6OHDA. Interestingly, the 6OHDA effects were ameliorat-
ed by intracerebral HSPC transplantation, which successfully prevented6OHDA-induced neurodegeneration of DA cells (DA cells, 23.44±5.05%
loss of control levels; ﬁbers, 26.25% ± 9.29% loss of control levels; with
no statistically signiﬁcant difference with respect to the Saline group)
(Fig. 1h). These data obtained for the 6OHDA mice, as with those
Fig. 2. Hematopoietic stem and progenitor cells spontaneously fuse with brain somatic cells in vivo. (a) Outline of the experimental design to detect cell-fusion events. Hybrids were
detected by the Cre/loxP system, where Cre-recombinase is under the control of the CAG promoter. Mice were transplanted with lineage-depleted (Lin-) HSPCs after saline and MPTP
treatment. Cre-mediated excision of the Stop codon in ﬂoxed-loxP transgenic mouse (R26Y), allowing yellow ﬂuorescent protein (YFP) expression. (b) Representative coronal
immunostaining sections of adult mouse midbrain showing tyrosine hydroxylase (TH, red) and yellow ﬂuorescent protein (YFP, green) immunopositive cells from the saline
and MPTP-treated mice. Cell nuclei were counterstained with DAPI (blue). Contralateral (nongrafted) and ipsilateral (grafted) sites are indicated. Scale bar: 400 μm. Representative
higher magniﬁcation images are as indicated for the white boxes. TH and YFP immunostaining revealed the double-positive cells (arrows). Scale bar: 50 μm. (c) Quantiﬁcation of the
YFP-immunopositive cells found per DAPI+ nucleus in the saline and MPTP-treated mice. Data are means ± s.e.m (5 sections/mouse; n= 6). Statistical analysis is based on Student's
t-tests. *P b 0.05.
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transplantation after damage promotes the survival of the endogenous
dopaminergic neurons in the SNpc.
3.2. HSPCs Transplanted Above the SNpc can Fuse with Neurons and
Glial Cells
We have previously shown that transplanted HSPCs can fuse with
retinal neurons (Sanges et al., 2013), and thus we aimed here to also
determine the occurrence of fusion events in the SNpc. HSPCs puriﬁed
from donor mice expressing Cre recombinase under the CAG promoter
(HSPCsCre) were unilaterally transplanted above the right SNpc of
Rosa26-LoxP-Stop-LoxP-YFP (R26Y) transgenic mice (Fig. 2a, Fig. S2a).
Shortly after transplantation, the fusion events, i.e., the hybrids detected
by yellow ﬂuorescent protein expression (YFP+), were found in theFig. 1. HSPC transplantation functionally rescued dopaminergic neurons. (a) Representation of
Midbrain area (MB), substantia nigra pars compacta (SNpc), ventral tegmental area (VTA), an
mice were evaluated for time to stimulus removal (from 1 to 4 weeks after transplantation)
transplantation). (c) Representative coronal sections of each group of mice (MPTP model) sh
and midbrain. (d) Quantiﬁcation of the number of TH+ neurons in the midbrain by ster
MPTP + HSPCs (n = 11), MPTP + HSPCs (Dkk1) (n = 7), and MPTP + Dkk1 (n = 7) trans
determined by the DOPAC/DA and HVA/DA ratios. DA, dopamine; CPu, striatum/caudate
transplanted mice were assessed for forepaw akinesia using the cylinder test. (g) Representa
(6OHDA model). (h) Percentage of TH+ neurons and ﬁbers loss in the 6OHDA + Sham (n =
(n = 7) transplanted mice, relative to intact (Saline) side. RH, Right hemisphere; LH, left
followed by Bonferroni's multiple comparison post-hoc tests. *P b 0.05; **P b 0.01; ***P b 0.001SNpc and not in the contralateral non-grafted hemisphere. These
YFP+ cells were scattered in the ventral midbrain 24 h after transplan-
tation, and some of them were also positive for the dopaminergic
neuron marker tyrosine hydroxylase (i.e., TH+) (Fig. 2b, right zooms).
The MPTP damage greatly increased the fusion of the transplanted
cells (Fig. 2c, Fig. S2a).
A marked inﬂammatory response induced reduction of the hybrids
by 7 days after transplantation (Fig. S2b). An increased density of glial
ﬁbrillary acidic protein (GFAP)-positive astroglia delineated the graft
(Fig. S2c), which was positively immunostained for the microglia/
macrophage marker CD11b, and for the activated microglia marker
CD68 (Fig. S2c). Corresponding regions in the contralateral hemisphere
and in the sham controls showed glial cell accumulation due to the
MPTP-induced damage, or to both MPTP and the needle insertion,
respectively (Fig. S2d, e).a sagittal brain section and a coronal section, indicating the site of HSPC transplantation.
d striatum (Str). (b) MPTP + Sham (n = 8) and MPTP + HSPCs (n = 11) transplanted
and for spontaneous activity upon quantiﬁcation of the number of rears (4 weeks after
owing immunohistochemistry of endogenous tyrosine hydroxylase (TH) in the striatum
eology, and TH+ striatal ﬁbers by optical densitometry, in MPTP + Sham (n = 11),
planted mice, relative to Saline (n = 8) transplanted mice. (e) Striatal DA turnover, as
-putamen; Ctx, cortex. (f) 6OHDA + Sham (n = 6) and 6OHDA + HSPCs (n = 10)
tive coronal sections showing TH immunohistochemical labeling for each group of mice
9), 6OHDA + HSPCs (n = 10), 6OHDA + HSPCs (Dkk1) (n = 8) and 6OHDA + Dkk1
hemisphere. Data are means ± s.e.m. Statistical analysis is based on one-way ANOVA
compared with Saline; n.s, not signiﬁcant; s, seconds.
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in the midbrain. Most of the YFP+ cells co-expressed the neuronal
nucleus protein (NeuN). A small percentage co-expressed GFAP,or the macrophage/microglia marker CD11b. None of the YFP+ cells
co-expressed the oligodendrocyte marker (CNPase) (Fig. 3a, b). Thus,
the majority of the HSPCs can fuse with neurons and some with glial
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ventral midbrain transcription factor (FoxA2) and with TH, both of
which are markers of dopaminergic neurons (Fig. 3c). TH is down-
regulated after MPTP administration (Jackson-Lewis et al., 1995), and
therefore we might have underestimated the number of YFP+TH+,
double-positive, cells. In contrast, the YFP+ cells never co-localized
with the GABAergic neuron markers γ-aminobutyric acid (GABA) and
glutamic acid decarboxylase (GAD) (Fig. 3d).
3.3. Hybrids Undergo Reprogramming In Vivo One Week After
HSPC Transplantation
Wenext analyzed the presence of the hybrids at different times after
the transplantation. HSPCsCre/RFP (isolated from mice carrying β-Actin-
Cre and the CAG-RFP alleles) were unilaterally grafted at day 3 after
the last MPTP intraperitoneal injection in R26Y mice (Fig. S3a), which
corresponds to the peak of apoptotic cell death in this model (Vila
et al., 2001). Control mice (injected with saline instead of MPTP) were
also grafted. One week after transplantation, there were high numbers
of RFP+YFP+ hybrids (Fig. 3e) with round and oval morphologies in
the MPTP-treated mice, which were higher than for the saline-treated
group (Fig. 3f). Some hybrids were localized throughout the right
ventralmidbrain site, close to the SNpc, in the parenchyma,while others
showed apparent association with vascular elements (Fig. 3e). As
expected, due to themarked inﬂammatory response (S2b–c), the num-
ber of surviving hybrids largely decreased 1 week after transplantation
as quantiﬁed by ﬂow cytometry (FACS) analysis (Fig. 3g).
The change in morphology of the RFP+YFP+ hybrids indicated a
possible reprogramming process (Acquistapace et al., 2011). Therefore
we analyzed changes in the transcription proﬁles of the hybrids
(RFP+YFP+) and in the unfused RFP+ cells puriﬁed from the ventral
midbrain (Fig. S3b). In both cell populations, there was almost no ex-
pression of adult astroglial or neuronal gene markers (e.g., Gfap, NeuN,
Olig2, Foxa2, Map2), and down-regulation of the HSPC markers Cd34
and Runx1. Interestingly, there was higher activation of the pluripotent
gene Oct4 in these RFP+YFP+ hybrids, as well as of neuronal precursor
genes, such as Sox2 and Nestin, with respect to that observed in the un-
fused (RFP+) cells (Fig. 3h). In contrast, endoderm and mesoderm lin-
eage markers were not up-regulated in the RFP+YFP+ cells, which
overall suggests that the hybrids commit toward neuroectoderm differ-
entiation (Fig. 3h).
Next, to further investigate the reprogrammed phenotype of
the hybrids genome-wide, we analyzed the transcriptome of the
RFP+YFP+ cells compared to the RFP+ unfused cells using microar-
rays. A large number of genes were up-regulated in the RFP+YFP+
hybrids with respect to the RFP+ cells (Table S1). Gene ontology (GO)
analysis of the up-regulated genes showed a statistically signiﬁcant en-
richment of genes associated with the GO term tissue morphogenesis
only in the hybrids (Fig. S3c; Table S2). Overexpression of this set of
genes is indicative of a reprogramming process and is in line with the
emerging concept of in vivo neuronal reprogramming (Amamoto and
Arlotta, 2014). Furthermore, gene-set enrichment analysis
(Subramanian et al., 2005) showed that hematopoietic stem and pro-
genitor genes were signiﬁcantly down-regulated in the RFP+YFP+Fig. 3. Characterization of hybrids formed in vivo. (a–d) R26Ymice transplanted as described in
immunostaining sections of midbrain areas where co-localization of YFP-immunopositive c
macrophage/microglia (CD11b), and oligodendrocyte (CNPase) markers are shown. Represe
(b) Cell number analysis of the YFP-immunopositive cells showing co-localization with NeuN
localization of YFP-immunopositive cells with TH (red) and FoxA2 (magenta) at the single-ce
do not co-localize with glutamic acid decarboxylase (GAD, red) and γ-aminobutyric acid (GA
Fig. 1a and sacriﬁced 1 week after transplantation (n = 4 each). (e) Representative immunos
(RFP, red) in the midbrain of MPTP and saline-treated mice. Some cells showed association
RFP+ cells in the saline and MPTP-treated mice (6 sections/mouse; n= 4). (Right) Percentag
(g) (Left) Quantiﬁcation of FACS-sorted RFP+ and RFP+YFP+ cells from MPTP-treated mice
at day 7 post-transplantation calculated with respect to the total transplanted cells (60,000
RFP+ FACS-sorted cells (3 mice/group). In all the immunostaining sections, the cell nuclei we
on Student's t-tests. **P b 0.01; ***P b 0.001.hybrids (False discovery rate; FDR b 25%), while neurogenesis genes
were enriched (Fig. S3d), further indicating reprogramming toward a
neuronal lineage.
Overall these data showed that the hybrids that formed in vivo
undergo reprogramming and morphological changes by 1 week after
HSPC transplantation.
3.4. Hybrids Acquire Astroglia Features and Survive Over the Long-term
After Transplantation
Four weeks after the intracerebral transplantation, in the MPTP-
treated mice, RFP+YFP+ cells located in the ventral midbrain near
the SNpc exhibited a morphology typical of glial cells (Fig. 4a). They
did not participate in scar formation, as they were not located in the
needle track nor in the transplantation site (Fig. S4a). These glial cells
showed highly branched ﬁne processes that often contacted the base-
ment membrane that surrounds blood vessels. In the MPTP-treated
mice, there were more RFP+ cells than in the Saline-treated mice, and
4.75 ± 1.61% of the RFP+ cells were also YFP+ (Fig. 4b, Fig. S4b).
Glial cells that are positive only for RFP suggest possible
transdifferentiation from the unfused HSPC-transplanted cells, or
silencing of the YFP transgene in the hybrids. Furthermore, we also
observed a few YFP+ (RFP-) cells, which were probably hybrids that
had switched off the RFP transgene (Fig. 4a).
Most of the RFP+ and YFP+ cells partially co-expressed the
astroglial marker GFAP (Fig. 4c). None of the highly branched RFP+
andYFP+cells co-expressed themicroglialmarker CD11b or the neuro-
nal marker NeuN (Figure S4c). Nevertheless, we observed some RFP+
cells with a smaller and less-branched shape that showed partial co-
localization with CD11b (Figure S4d). Thus, by 4 weeks after transplan-
tation, the RFP+YFP+ cells had mainly acquired properties of mature
astroglial cells, and did not express neuronal markers.
We further validated whether the hybrids after fusion of HSPCswith
glial cells acquired features ofmature astroglia over the long-term. Thus,
we grafted HSPCsR26Y into MPTP-treated GFAP-Cre mice, which express
Cre only in astroglia (Fig. 4d). Four weeks after transplantation, we
observed that YFP+ cells localized in the diseased ventral midbrain
associated with GFAP+ astroglial cells (Fig. 4e). Their levels were
5.42 ± 0.38% with respect to the total GFAP+ cell population. Interest-
ingly, this percentage was considerably high considering that after
transplantation they were 1.52 ± 0.37% (Fig. 4f). Most of the YFP+
cells co-expressed GFAP (89.75 ± 6.19%) or the mature astrocyte-
speciﬁc cytosolic protein S100β (Fig. 4g, h). Moreover, some cells also
expressed the neuroprogenitor marker Sox2 (Fig. 4i), which suggests
that some of the hybrids were reprogrammed. Instead, they did not
co-express oligodendrocyte transcription factor 2 (Olig2) or microglia
marker Iba-1 (Fig. S4e). There were low levels of YFP-positive cells
that were not astroglial cells (10.25% ± 6.19%; Fig. 4h), although we
could not identify their nature through marker analysis.
We foundGFAP+YFP+hybrids 4weeks after transplantation also in
the 6OHDA Parkinson's disease model (Fig. S4f). The YFP+ cells co-
localized with Cre in the sections from both MPTP- and 6OHDA-
transplanted mice, further conﬁrming that the YFP+ cells were indeed
hybrids (Fig. S4 g).the legend to Fig. 1a were sacriﬁced 24 h after transplantation (n=6). (a) Representative
ells with neuronal nuclei protein (NeuN, red), glial ﬁbrillary acid protein (GFAP, red),
ntative higher magniﬁcation zooms from the white boxes are shown. Scale bar: 50 μm.
, GFAP, MAC-1, and CNPase (5 sections/mouse; n= 6). (c) Immunostaining showing co-
ll level. Arrows indicate co-localization. Scale bar: 50 μm. (d) YFP-immunopositive cells
BA, red). (e-h) MPTP and saline-treated R26Y mice were transplanted as in the legend to
taining sections from YFP-immunopositive cells co-labeled with red ﬂuorescent protein
with vascular elements (dashed line). Scale bar: 50 μm. (f) (Left) Quantiﬁcation of the
e of the double-positive cells (RFP+YFP+) in the saline and MPTP-treated mice (n= 4).
1 week after transplantation. (Right) Percentage of surviving RFP+ and RFP+YFP+ cells
). (h) qRT-PCR analysis of the expression of the indicated genes in the RFP+YFP+ and
re counterstained with DAPI (blue). Data are means ± s.e.m. Statistical analysis is based
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sion of transplanted HSPCs with glial cells, or the hybrids that acquire
astroglia features over the long-term, survive up to 4 weeks after the
surgery. To further demonstrate this, we grafted HSPCsR26Y into MPTP-
treated FoxA2-Cre mice, to obtain neuron-derived hybrids to followover the long-term after transplantation (Fig. S4 h). We could not ﬁnd
YFP+ cells with astroglial or neuronal morphologies 4 weeks after
transplantation, but only at early time points, further suggesting that
neuron-derived hybrids do not survive (Fig. S4i-j). In addition, we
FACS-sorted RFP+YFP+ hybrids and RFP+ cells (obtained after
91W. Altarche-Xifro et al. / EBioMedicine 8 (2016) 83–95transplanting HSPCsR26Y in MPTP-treated GFAP-Cre or in MPTP-treated
FoxA2-Cre mice) and analyzed their transcriptome proﬁle by microar-
ray analysis. Of note, the RFP+YFP+ hybrids obtained from the GFAP-
Cre mice were analyzed 7 days after transplantation. Instead the
RFP+YFP+ hybrids obtained from the FoxA2-Cre mice were analyzed
5 days after transplantation, as their numbers at 7 days after transplan-
tation were already very low and were not sufﬁcient to perform
genome-wide analysis. We performed gene-set enrichment analysis
on the up-regulated genes in the hybrids, and we observed that the
RFP+YFP+hybrids obtained from theGFAP-Cremiceweremore signif-
icantly enriched (FDR b 25%) in neurogenesis genes than those obtained
from the FoxA2-Cre mice (Fig. S3e, Tables S3 and S4), further indicating
that glial-derived hybrids undergo reprogramming and survive longer.
These results are also in agreement with the observation that the
RFP+YFP+ hybrids obtained from the R26Y mice display enrichment
in neurogenesis genes albeitwith high FDR (Fig. S3d), since they include
glial- and neuron-derived hybrids. Overall, these data indicate that hy-
brids formed by HSPCs with neurons appear not to survive over the
long-term, as opposed to the glial-derived hybrids.
3.5. Activation of theWnt Signaling Pathway is Essential for PD Rescue After
HSPC Transplantation
The Wnt signaling pathway has a key role in neuronal cell survival
and homeostasis (Inestrosa and Arenas, 2010). Moreover, MPTP treat-
ment itself induces temporal and dynamic changes in Wnt signaling
components during dopaminergic degeneration (L'episcopo et al.,
2010). Consequently, we investigated the changes in Wnt signaling
after HSPC transplantation in MPTP-injured mice. We dissected out
the ventral midbrain area of transplanted MPTP-treated and saline-
treatedmice, and observed that the protein levels of the transcriptional-
ly active form of β-catenin underwent signiﬁcant up-regulation in
HSPC-transplanted mice when the lesion was stabilized (Vila et al.,
2001) (Fig. S5a, b). Accordingly, the direct Wnt/β-catenin targets
Axin2 and the canonical Wnt pathway receptor Fzd1 were up-
regulated (Fig. S5c). In contrast,Wnt5a, which is a regulator of the non-
canonical pathway, did not change (Fig. S5c). Interestingly, GFAPmRNA
(Fig. S5d) and protein (Fig. S5e, f) also increased, which suggests that
activation of astroglial cells in the midbrain of the transplanted mice
correlates with activation of Wnt signaling after HSPC transplantation.
Finally, we observed reduced levels of Caspase-9 expression in
the HSPC-transplanted mice, which was comparable to the level in the
Saline group, thus indicating reduced apoptosis in the treated mice
(Fig. S5g).
Astroglial cells produce Wnt1 (L'episcopo et al., 2010; Zhang et al.,
2015), which has been shown to have a trophic effect on neighboring
neurons in vitro (L'episcopo et al., 2011). We conﬁrmed secretion of
Wnt1 by astroglia in vivo along the caudal and rostral aqueduct, which
is an area that is enriched in astroglia; the rostral area is closest to the
transplantation site in the ventral midbrain (Fig. S5h). Interestingly,
Wnt1 was internalized by the nearby neurons (Fig. S5h). With this in
mind, we analyzed and observed that glial-derived hybrids also secrete
Wnt1 (Fig. 5a), which suggests its protective effect on the surrounding
dopaminergic neurons. Wnt1 transcript and protein levels wereFig. 4. Hybrids can acquire features of GFAP-expressing astroglial cells 4 weeks after transplan
4 weeks after transplantation (n = 4). (a) Representative immunostaining sections of midbr
YFP or RFP single-positive cells with glial morphology are also shown. Scale bar: 20 μm. (b) Q
(green) and RFP+ (red) cells expressing the astroglial cell marker GFAP (magenta). Scale bar:
used in (e–i). Cre recombinase is under the control of the GFAP promoter, allowing identiﬁ
(n= 4). (e) Representative immunostaining sections showing YFP+ cells (green) co-express
fusion quantiﬁed 24 h (24hPT) and 4 weeks (4wPT) post-transplantation as the number of YF
(green) hybrids co-localize (arrows) with GFAP (red) and S100β (red) markers. Arrowhea
YFP+GFAP- cells. (i) Hybrid reprogramming is shown by triple immunostaining for YFP (gree
cell nuclei were counterstained with DAPI (blue). Data are means ± s.e.m. Statistical analysis isigniﬁcantly increased in the ventral midbrain after MPTP administra-
tion andHSPC transplantation,with respect to the Saline and Sham con-
trols (Fig. 5b, c, Fig. S5i), which indicates increased Wnt1 secretion,
which is probably dependent on the hybrids.
As the presence of hybrid-derived astroglia correlated with the
observed functional rescue of PD, and at the same time we observed
activation of the Wnt/β-catenin canonical pathway in the transplanted
area and secretion of Wnt1 by the hybrids, we aimed to address the
effect of the block of Wnt/β-catenin signaling activity in the HSPC-
transplanted mice. Remarkably, treatment with the Wnt antagonist
Dkk1 (unilateral infusion in the SNpc) impaired the recovery of dopami-
nergic neurons mediated by HSPCs in both the MPTP and 6OHDA
models (Fig. 1c, d, f, g), which suggests that activation of the pathway
is essential for the observed rescue phenotype.
As a ﬁnal demonstration that ablation of the hybrids can impair the
rescue, we used transgenic mice carrying the Rosa26-LoxP-STOP-LoxP-
DTR (R26-diphtheria toxin receptor) and transplanted these with
HSPCsCre/RFP (Fig. 5d). After fusion, the hybrids expressed both RFP
and DTR, making them sensitive to diphtheria toxin (DT) injection;
thus, they were selectively ablated (Fig. S5j). Four weeks after trans-
plantation, the percentages of TH+ ﬁbers and TH+ neurons were
very low in both the Sham and HSPC-transplanted mice that received
the toxin (Fig. 5e, f), which indicates that ablation of the hybrids impairs
the observed rescue.
4. Discussion
Current cell-therapy strategies in PD models are based on the trans-
plantation of a variety of different cell types into the striatum with the
aim of obtaining DA release (Meyer et al., 2010; Gaillard and Jaber,
2011). Release of DA has been shown to occur directly from grafted
neural stem cells obtained after differentiation of human embryonic
stem cells (Kang et al., 2014). However, the transplanted cells usual-
ly do not integrate into the existing basal ganglia circuit, and they
are only likely to function as DA producers (Gaillard and Jaber,
2011). In the present study, we aimed to identify ways to function-
ally rescue the dopaminergic loss in the physiological context; i.e.,
in the SNpc.
We and others have previously shown that BM-derived cells can
fuse with neurons and glial cells in damaged retina and in different
damaged brain areas, with functional correction of disease (Johansson
et al., 2008; Sanges et al., 2013). Here, we found fusion of HSPCs with
TH+ cells, and not with GABA+ or GAD+ cells. This might be because
the MPTP-damaged TH+ neurons can release factors that promote
fusionwith transplantedHSPCs. TheGABA+andGAD+neurons are in-
stead not damaged by the MPTP treatment. Interestingly, we found hy-
brids located well away from the injection site in the PDmodels, which
leads us to speculate that these can migrate upon inﬂammation-
mediated chemo-attraction.
Reprogramming of hybrids and their following differentiation into
functional retinal neurons has been observed before (Sanges et al.,
2013), which suggests that the hybrids are an important source of
new cells in the repair of central nervous system function (Lluis and
Cosma, 2010). Furthermore, transient expression of precursor andtation. (a–c) R26Y mice transplanted as described in the legend to Fig. 1a were sacriﬁced
ain areas showing YFP+ cells (green) with glial morphology co-labeled with RFP (red).
uantiﬁcation of RFP+YFP+ cells in the saline and MPTP-treated mice (n= 4). (c) YFP+
50 μm. (d) Schematic representation of the transplantation scheme and of mouse strains
cation of astroglial-derived hybrids. Mice were sacriﬁced 4 weeks after transplantation
ing the astroglial marker (GFAP, red). Arrows indicate hybrids. Scale bar: 100 μm. (f) Cell
P+GFAP+ cells with respect to the total GFAP+ cells (6 sections/mouse; n= 4). (g) YFP
ds indicate YFP+GFAP- cells. Scale bar: 20 μm. (h) Quantiﬁcation of YFP+GFAP+ and
n), Sox2 (red), and GFAP (magenta). Scale bar: 20 μm. In all immunostaining images, the
s based on Student's t-tests. ***P b 0.001; n.s: not signiﬁcant.
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transdifferentiation or in vivo cell fusion (Sanges et al., 2013; Bar-Nur
et al., 2015). Whether the transient re-expression of pluripotency
genes is a driver for efﬁcient differentiation of the hybrids into the
correct lineage still remains to be deﬁned.
Here, we showed that the presence of glial-derived hybrids correlat-
ed with the functional rescue of PD. Although the hybrids underwentreprogramming by expressing precursor markers, we did not observe
relevant conversion of the hybrids into newly generated dopaminergic
neurons. It is possible that other additional signals thatwere not activat-
ed under our experimental conditions are necessary for the hybrids to
be eventually differentiated into neurons. Alternatively, timing
might also be a critical variable; i.e. possible few hybrids committed
to differentiation in neurons in the brain might need a long time.
93W. Altarche-Xifro et al. / EBioMedicine 8 (2016) 83–95On the other hand, the transplantation of HSPCs appears to induce
protection against dopaminergic neuron loss due to a niche-mediated
effect of the glial-derived hybrids, which release Wnt1 and perhaps
other to-be-identiﬁed neurotrophic factors.
Previously, it was shown that the Wnt1 transcript is strongly in-
duced in MPTP-reactive astroglia, and the release of Wnt1 from these
cells was suggested (L'episcopo et al., 2010, 2014b; Zhang et al., 2015).
Our data show here that Dkk1-mediated blockade of the endogenous
Wnt/β-catenin pathway impairs the observed rescue, which suggests
that the already high levels of the endogenous Wnt pathway after the
MPTP and 6ODHA treatments is sufﬁcient to activate the transplanted
HSPCs.
We found that Wnt1 is efﬁciently secreted from astroglia in the
aqueduct of the caudal area in adult mice, and also in the rostral area,
which is closest to the area of transplantation in the ventral midbrain.
It is known that the activation of canonical Wnt/β-catenin signaling
can prevent secretion of pro-inﬂammatory cytokines from the microg-
lia, and alongwith the recognized role of astroglia as a source of survival,
neurotrophic, and neurogenic factors, this can favor the rescue of DA
neurons (L'Episcopo et al., 2014a).
A glial-cell-mediated niche effect might well be a way to protect
nigral dopaminergic neurons from neurotoxin-induced cell death.
Optogenetically activated astrocytes in the MPTP mouse model were
shown to produce basic ﬁbroblast growth factor, which in turn en-
hanced the dopaminergic differentiation of transplanted human embry-
onic stem cells, and also protected against dopaminergic neuron loss
(Yang et al., 2014). Overall, dopaminergic neuron plasticity and survival
can be sustained by trophic factors released by nearby astroglial cells,
which might become an important target for PD therapy (Marchetti
et al., 2013).
In our cell-therapy approach, although we observed a signiﬁcant
amelioration of the dopaminergic neuron loss, there was also a drastic
decrease in the hybrids already 1 week after transplantation. This was
due to the immune response against the graft. In the future if a way to
enhance the survival of the hybrids can be identiﬁed, it is likely that
the observed functional rescue will be much increased. Also the ectopic
activation of theWnt pathway in the transplanted cells or directly at the
site of transplantation might be beneﬁcial in aged mice, where it has
been shown that the damage-dependent activation of the pathway is
not so relevant (L'episcopo et al., 2010). Along with Wnt signaling
activation, the use of molecules that can enhance differentiation of the
hybrids, such as brain-derived neurotrophic factor (BDNF) and glial
cell-derived neurotrophic factor (GDNF) (Deierborg et al., 2008; Enciu
et al., 2011) might also be beneﬁcial for improving the rescue of the
PD phenotype.
Unilateral transplantation of HSPCs in the bilateral MPTP-damaged
mice resulted in a greater number of surviving TH+ neurons ipsilateral
to the graft, compared to animals transplanted with PBS (i.e., the Sham
group). On the other hand, the transplantation of one side can also be
propagated to the other side, as the GFAP-derived hybrids secrete neu-
rotrophic factors, and these can diffuse through both hemispheres and
rescue the defects bilaterally (Sieber-Blum, 2010). Previous published
data have shown rescue of contralateral non-transplanted sites in the
MPTPmouse model (Ourednik et al., 2002, 2009). Indeed, we observed
a tendency (although, as expected, it did not reach signiﬁcance) forFig. 5.Newly generated hybrid-derived astroglia secrete Wnt1. (a) Wnt1 protein (red) co-loca
transplanted mice sacriﬁced 4 weeks after transplantation. Scale bar: 50 μm. Representative
images, cell nuclei were counterstained with DAPI (blue). (b, c) Quantiﬁcation of Wnt1 m
housekeeping gene and protein, β-Actin, was used to normalize the qRT-PCR and Western blo
6/group). Statistical analysis is based on one-way ANOVA followed by Bonferroni's multiple
transplanted as described in the legend to Fig. 1a were sacriﬁced 4 weeks after transplantat
immunohistochemistry of endogenous TH in the striatum and midbrain. (f) Quantiﬁcation o
optical densitometry, in MPTP + Sham (n = 9), MPTP + HSPCs (n = 10) and MPTP + HS
hemisphere; LH, left hemisphere. Data are means ± s.e.m. Statistical analysis is based on o
compared to Sham; n.s, not signiﬁcant.the rescue of the non-transplanted hemisphere at the level of both the
ﬁbers and the cell bodies. This was also evident (although only as a
trend)whenwemeasured themetabolite to DA ratio in the contralater-
al side, both in the cortex and the striatum.
Overall, our data here suggest that our approach can be efﬁcient for
the rescue of both hemispheres; however to increase efﬁcacy, several
clinical trials have reported that bilateral transplantation might be
necessary (Peschanski et al., 1994; Defer et al., 1996; Venkataramana
et al., 2010, 2012).
In conclusion, our data show that reprogramming of HSPC-derived
hybrids and their acquisition of mature astroglial features indicate
fusion-mediated plasticity of adult neural cells in vivo. HSPC-mediated
fusion appears to be an efﬁcient approach to prevent neuronal loss
and to rescue neurobehavioral function in PD. Importantly, HSPCs are
already used in the clinic (Deda et al., 2009; Chen et al., 2014a, 2014b;
Park et al., 2015), which suggests their safety, and therefore this cell-
therapy method might be translated into the clinic smoothly.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.04.016.
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